Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide BCise: 6-month follow-up from US real-world data.
Diabetes Mellitus, Type 2
/ drug therapy
Drug Administration Schedule
Exenatide
/ therapeutic use
Female
Follow-Up Studies
Glucagon-Like Peptide-1 Receptor
/ therapeutic use
Glucagon-Like Peptides
/ analogs & derivatives
Glycated Hemoglobin
/ analysis
Humans
Hypoglycemic Agents
/ therapeutic use
Immunoglobulin Fc Fragments
/ therapeutic use
Male
Middle Aged
Recombinant Fusion Proteins
/ therapeutic use
GLP-1
dulaglutide
exenatide
type 2 diabetes
Journal
Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
14
07
2020
revised:
29
08
2020
accepted:
12
09
2020
pubmed:
19
9
2020
medline:
6
7
2021
entrez:
18
9
2020
Statut:
ppublish
Résumé
To compare 6-month adherence, persistence and treatment patterns among patients initiating once-weekly glucagon-like peptide-1 receptor agonists (GLP-1RAs), dulaglutide versus semaglutide, and dulaglutide versus exenatide BCise, using claims from the HealthCore Integrated Research Database. Patients aged ≥18 years, with type 2 diabetes, ≥1 claim for dulaglutide, semaglutide or exenatide BCise during the index period February 2018 to December 2018 (index date = earliest GLP-1RA fill date), no claim for GLP-1RAs in the 6-month pre-index period, and continuous enrolment 6 months pre- and post-index were included. Dulaglutide users were propensity-matched 1:1 to semaglutide users (3852 pairs) or exenatide BCise users (1879 pairs). The proportions of adherent (proportion of days covered ≥80%) patients were compared using chi-squared tests. Persistence, measured as days to discontinuation, was analysed using a Cox regression model. Matched cohorts (dulaglutide:semaglutide and dulagutide:exenatide BCise) were balanced in baseline characteristics and the mean age was 54 and 55 years, respectively, with approximately 51% and 49% women, respectively. At 6 months, significantly more dulaglutide users were adherent than semaglutide (59.7% vs. 42.7%; P <0.0001) or exenatide BCise users (58.1% vs. 40.3%; P <0.0001). Cox regression showed that dulaglutide users were less likely to discontinue therapy than semaglutide (hazard ratio [HR] 0.71, 95% confidence interval [CI] 0.66, 0.76) or exenatide BCise users (HR 0.59, 95% CI 0.53, 0.65; P <0.0001, both). At 6-month follow-up, a higher proportion of patients initiating dulaglutide were adherent to and persistent with their treatment, compared to matched patients initiating either semaglutide or exenatide BCise.
Identifiants
pubmed: 32945083
doi: 10.1111/dom.14195
pmc: PMC7756843
doi:
Substances chimiques
Glucagon-Like Peptide-1 Receptor
0
Glycated Hemoglobin A
0
Hypoglycemic Agents
0
Immunoglobulin Fc Fragments
0
Recombinant Fusion Proteins
0
semaglutide
53AXN4NNHX
Glucagon-Like Peptides
62340-29-8
Exenatide
9P1872D4OL
dulaglutide
WTT295HSY5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
106-115Informations de copyright
© 2020 Eli Lilly and Company. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
Références
Clin Ther. 2011 Jan;33(1):74-109
pubmed: 21397776
Int J Clin Pract. 2008 Jan;62(1):76-87
pubmed: 17983433
Manag Care Interface. 2006 Jul;19(7):31-41
pubmed: 16898343
Diabetes Care. 2020 Jan;43(Suppl 1):S98-S110
pubmed: 31862752
Diabetes Obes Metab. 2019 Apr;21(4):920-929
pubmed: 30520248
Curr Med Res Opin. 2018 Jun;34(6):995-1003
pubmed: 29271258
Value Health. 2015 Jun;18(4):530-40
pubmed: 26091607
Diabet Med. 2015 Jun;32(6):725-37
pubmed: 25440507
Lancet Diabetes Endocrinol. 2018 Apr;6(4):275-286
pubmed: 29397376
BMJ Open Diabetes Res Care. 2019 Dec 9;7(1):e000884
pubmed: 31875137
Med Care. 2005 Jun;43(6):521-30
pubmed: 15908846
Diabetes Care. 2014 Jan;37 Suppl 1:S81-90
pubmed: 24357215
Am J Manag Care. 2012 Nov;18(11):721-6
pubmed: 23198714
PLoS One. 2015 Feb 24;10(2):e0118296
pubmed: 25710465
Diabetes Obes Metab. 2021 Jan;23(1):106-115
pubmed: 32945083
Clin Ther. 2016 Jan 1;38(1):149-60
pubmed: 26706658
Med Care. 2005 Nov;43(11):1130-9
pubmed: 16224307
Patient Prefer Adherence. 2017 Jun 30;11:1103-1117
pubmed: 28721024
Patient Prefer Adherence. 2016 Jul 22;10:1299-307
pubmed: 27524885
Adv Ther. 2014 Nov;31(11):1119-33
pubmed: 25408484
Stat Sci. 2010 Feb 1;25(1):1-21
pubmed: 20871802
J Diabetes Res. 2016;2016:9687815
pubmed: 27579326
Patient Prefer Adherence. 2015 Jan 23;9:139-49
pubmed: 25670885
Adv Ther. 2015 Apr;32(4):341-55
pubmed: 25832470
Diabetes Ther. 2018 Jun;9(3):1169-1184
pubmed: 29675797
Diabetes Obes Metab. 2017 Jul;19(7):953-961
pubmed: 28181725
Diabetes Care. 2020 Feb;43(2):487-493
pubmed: 31857443
Diabetes Metab Res Rev. 2016 Nov;32(8):776-790
pubmed: 27102969
Can J Diabetes. 2019 Mar;43(2):136-145
pubmed: 30195966
Am Health Drug Benefits. 2014 Nov;7(8):452-63
pubmed: 25558307
Adv Ther. 2014 Dec;31(12):1287-305
pubmed: 25504156
Diabetes Obes Metab. 2020 Mar;22(3):355-364
pubmed: 31646727
Diabetes Care. 2017 Nov;40(11):1469-1478
pubmed: 28801475
Diabetes Manag (Lond). 2014 Jan 1;4(1):29-48
pubmed: 25214893
Diabetes Care. 2012 Dec;35(12):2533-9
pubmed: 22912429